These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39045914)

  • 1. Early intervention and cumulative life course impairment in psoriasis: a review.
    Arancio LMH; D'Amico D; Dastoli S; Fiorella CS; Manfredini M; Moretta G; Paolino G; Levi A; Di Fino S; Zucchi B; Piaserico S
    Clin Exp Dermatol; 2024 Nov; 49(12):1525-1531. PubMed ID: 39045914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis: is the impairment to a patient's life cumulative?
    Kimball AB; Gieler U; Linder D; Sampogna F; Warren RB; Augustin M
    J Eur Acad Dermatol Venereol; 2010 Sep; 24(9):989-1004. PubMed ID: 20477920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course.
    Warren RB; Kleyn CE; Gulliver WP
    Br J Dermatol; 2011 May; 164 Suppl 1():1-14. PubMed ID: 21477010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative life course impairment: evidence for psoriasis.
    Mattei PL; Corey KC; Kimball AB
    Curr Probl Dermatol; 2013; 44():82-90. PubMed ID: 23796812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cumulative life course impairment: identifying patients at risk.
    Augustin M
    Curr Probl Dermatol; 2013; 44():74-81. PubMed ID: 23796811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis.
    Romiti R; Magalhães RF; Duarte GV
    An Bras Dermatol; 2024; 99(2):269-276. PubMed ID: 38135557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative life course impairment: the imprint of psoriasis on the patient's life.
    Ros S; Puig L; Carrascosa JM
    Actas Dermosifiliogr; 2014 Mar; 105(2):128-34. PubMed ID: 23668623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' narratives.
    Foulkes AC; Warren RB
    Curr Probl Dermatol; 2013; 44():145-57. PubMed ID: 23796819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Measurement Tools to Assess Cumulative Life Course Impairment in Patients with Chronic Skin Diseases.
    Braren-von Stülpnagel CC; Augustin M; Westphal L; Sommer R
    J Eur Acad Dermatol Venereol; 2023 Feb; ():. PubMed ID: 36807404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases - a systematic review.
    von Stülpnagel CC; Augustin M; Düpmann L; da Silva N; Sommer R
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):2166-2184. PubMed ID: 33988873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting up a life course questionnaire.
    Sampogna F
    Curr Probl Dermatol; 2013; 44():67-73. PubMed ID: 23796810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Life course impairment and quality of life over time.
    Sampogna F
    Curr Probl Dermatol; 2013; 44():47-51. PubMed ID: 23796808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis - The Life Course Approach.
    Linder MD; Piaserico S; Augustin M; Fortina AB; Cohen AD; Gieler U; Jemec GB; Kimball AB; Peserico A; Sampogna F; Warren RB; de Korte J
    Acta Derm Venereol; 2016 Aug; 96(217):102-8. PubMed ID: 27283774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Depression and anxiety disorders among psoriasis patients: protective and exacerbating factors].
    Bangemann K; Schulz W; Wohlleben J; Weyergraf A; Snitjer I; Werfel T; Schmid-Ott G; Böhm D
    Hautarzt; 2014 Dec; 65(12):1056-61. PubMed ID: 25376619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis and the life cycle of persistent life effects.
    Garshick MK; Kimball AB
    Dermatol Clin; 2015 Jan; 33(1):25-39. PubMed ID: 25412781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative Life Course Impairment of Alopecia Areata.
    Burns LJ; Mesinkovska N; Kranz D; Ellison A; Senna MM
    Int J Trichology; 2020; 12(5):197-204. PubMed ID: 33531741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type D personality is associated with poor quality of life, social performance, and psychological impairment in patients with moderate to severe psoriasis: A cross-sectional study of 130 patients.
    Aguayo-Carreras P; Ruiz-Carrascosa JC; Molina-Leyva A
    Indian J Dermatol Venereol Leprol; 2020; 86(4):375-381. PubMed ID: 31857521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial stress affects the change of mental distress under dermatological treatment-A prospective cohort study in patients with psoriasis.
    Wintermann GB; Bierling AL; Peters EMJ; Abraham S; Beissert S; Weidner K
    Stress Health; 2024 Feb; 40(1):e3263. PubMed ID: 37243509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in psoriasis patients.
    Augustin M; Radtke MA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):559-68. PubMed ID: 24820452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.